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Abstract
Background: CD4+ T lymphocytes are the primary targets of HIV1 but cannot be infected when fully quiescent, due to a
post-entry block preventing the completion of reverse transcription. Chiu et al. recently proposed that this restriction
reflects the action of APOBEC3G (A3G). They further suggested that T cell activation abrogates the A3G-mediated block by
directing this protein to a high molecular mass complex.
Methodology/Principal Findings: In the present work, we sought to explore further this model. However, we found that
effective suppression of A3G by combined RNA interference and expression of HIV1 Vif does not relieve the restrictive
phenotype of post-activation resting T cells. We also failed to find a correlation between HIV resistance and the presence of
A3G in a low molecular complex in primary T cells.
Conclusions/Significance: We conclude that A3G is unlikely to play a role in the HIV restrictive phenotype of quiescent T
lymphocytes.
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Introduction
CD4+ T lymphocyte cells are the primary in vivo targets of
HIV1. However, early studies made it clear that, both in vivo and in
vitro, these cells are refractory to HIV1 infection when in a
quiescent state. Indeed, after viral entry into resting T cells, reverse
transcription is initiated but fails to reach completion [1]. CD4+ T
lymphocytes isolated from peripheral blood (PB) become permis-
sive to HIV1 replication once activated through the T cell receptor
or stimulated in vitro with cytokines such as interleukin-2 (IL-2), IL-
7 and IL-15. Accordingly, exposure to cytokines secreted in vivo in
the microenvironment of lymphoid tissues might explain why
resident naı¨ve CD4+ T cells are permissive to the virus [1–5].
The differential expression of cellular factors in resting and
activated T cells has been proposed as an explanation for these
observations (reviewed in [6,7]), but conclusive evidence for their
role has been lacking. Recently, apolipoprotein B mRNA editing
enzyme catalytic polypeptide 3G (APOBEC3G – A3G) has been
put forth as the post-entry restriction factor responsible for HIV1
restriction in resting CD4+ T cells [8]. A3G was initially
discovered as potent anti-HIV1 factor countered by the HIV vif
gene product [9]. Several studies demonstrated that this and
selected other cytidine deaminases, if expressed in vif-defective
(DVif) HIV1 producer cells, are packaged into outgoing retroviral
particles and lethally edit nascent viral reverse transcripts once the
virus enters target cells [10–12]. In recent work, Chiu et al.
reported that A3G, in resting CD4+ cells, is found in an
enzymatically active form within a low-molecular-mass (LMM)
complex, and based on RNAi-mediated depletion experiments
claimed that it was as such responsible for the HIV1 restriction
observed in these targets [8]. In contrast, in activated CD4+ cells,
A3G was noted to be present in high-molecular-mass (HMM)
ribonucleoprotein complexes as a catalytically inactive protein,
possibly explaining why it did not have such an effect. It was
further suggested that, in quiescent T cells, A3G could restrict
both wild-type and DVif HIV, since it was acting before
integration and viral protein production, and since only insignif-
icant amounts of Vif are present in incoming virions [8].
Stimulated by this interesting claim, we decided to explore the
mechanisms of A3G-mediated post-entry HIV1 restriction in resting
CD4+T cells. However, we report here that we found no evidence of
an antiviral effect of the cytidine deaminase in such a setting.
Results
In their work leading to the proposal that A3G is responsible for
restricting HIV in quiescent CD4+ cells, Chiu et al. down-regulated
the protein by siRNA tranfection [8]. In order to facilitate
subsequent mechanistic studies, we decided to use an alternative
model, in which activated CD4+ T lymphocytes were transduced
with lentiviral vectors carrying effector sequences, and analyzed for
HIV1 permissiveness once back to a resting and restrictive state. For
this, CD4+ T cells were purified from human PB (resting cells),
stimulated by IL2 and phytohemagglutinin (PHA) (activated cells)
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and led to rest again by decreasing IL-2 concentration in the culture
medium (resting post-activation cells) (Figure 1a). To validate our
model, we first compared the level of activation and susceptibility to
infection of the three populations, which were analyzed by flow
cytometry for the presence of activation markers and for GFP
expression following exposure to a GFP-expressing HIV reporter
virus. As expected, activated T cells expressed high levels of the
activation markers CD25 and CD69, and were susceptible to HIV
infection (68% of GFP+ cells). In contrast, resting post-activation
cells expressed negligible levels of activation markers and were fully
restrictive to HIV infection (0.1% of GFP+ cells), as were un-
activated resting cells (1% GFP+ cells) (Figure 1b).
In order to knock down A3G expression, we used a combined
protein- and RNA-based approach. We took advantage of the
HIV-1 Vif protein, which counters A3G by triggering its
proteasomal degradation [13,14]. We transduced activated T cells
with lentiviral vectors expressing wild type Vif or, as a control, the
C133S Vif mutant, which still interacts with A3G but fails to
induce its degradation [15]. We verified the functionality of wild-
type Vif by demonstrating that it could counter the effect of A3G
on DVif HIV-1 in activated T cells, in contrast to the C133S Vif
mutant (data not shown). Also, we transduced activated T cells
with lentiviral vectors expressing shRNA directed to A3G (shA3G)
or, as a control, a mismatched shRNA. We then tested A3G levels
of expression in the resting post-activation cells. Western blot
analysis with A3G specific antibody showed a reduction of the
A3G protein level of 90% on average when cells were transduced
with Vif- or shA3G-expressing vectors (Figure 2a).
Then, we evaluated the effect of A3G knock down on the
susceptibility to HIV infection of resting post-activation T cells.
We performed single-round infection experiments with VSV-G-
pseudotyped HIV reporter virus expressing GFP or CFP. T cells
expressing Vif or shA3G, or Vif C133S or the control shRNA,
were exposed to HIV reporter virus and analyzed 3 days later for
fluorescent protein expression. Despite the efficient down-
regulation of A3G, resting post-activation T cells were still as
restrictive to HIV infection (1.6% GFP+ cells on average, 2
experiments with shA3G- and 2 with Vif-expressing cells) as
untransduced or control-transduced cells (2.3% and 2.1% GFP+
cells, respectively; average of 4 experiments) (Figure 2b). This was
not due to a lack of infectivity of the reporter virus, because when
used at the same multiplicity of infection (MOI) in activated T cells
it efficiently induced stable GFP expression (Figure 2b). Based on
these data, we conclude that A3G does not mediate HIV
restriction in resting T cells.
Finally, to evaluate whether A3G was present in a low
molecular mass complex in resting post-activation CD4+ T cells,
as previously observed in resting CD4+ T cells [8], we performed
high speed centrifugation. This assay allows separating cytosolic
unbound A3G in the supernatant (SN) fraction form the higher
molecular forms of A3G in the pellet (P) fraction [16]. Resting,
activated and resting post-activation T cells were subjected to high
speed ultracentrifugation, and SN and P fractions from each
sample were subjected to Western blot analysis with an A3G-
specific antibody. As previously shown [16], resting cells showed a
2–3 fold higher SN/P ratio when compared to activated cells,
confirming that A3G in resting T cells is prevalently in a low
molecular mass form that shifts to a high molecular mass complex
when cells are activated. In contrast, the SN/P ratio in resting
post-activation T cells was comparable to the SN/P ratio in
activated cells, indicating that in these cells A3G is mostly present
in a high molecular mass complex (Figure 2c). Thus, there is no
correlation between the presence of A3G in a LMM complex and
a post-entry restriction of HIV1 infection.
Discussion
The resistance of resting T cells to HIV1 infection has been the
focus of numerous studies. While most have concurred to
demonstrate that this phenotype represents a post-entry bock to
reverse transcription, the mechanism at play and its cellular
mediators have remained elusive [1,2,17,18]. Recently, Chiu et al.
proposed that A3G was responsible for the observed restriction
[8]. However, this claim was challenged by Kamata et al. [19], who
did not observe any relief of HIV blockade following transfection
of A3G-specific siRNAs in quiescent CD4+ T cells, that is,
following the very same protocol as Chiu et al. Here, we studied
the question using a different experimental setting, albeit one in
which HIV1 restriction in quiescent T cells is fully revealed. In
order to down-regulate A3G, we transduced activated CD4+ T
cells with shRNA/Vif-expressing vectors and analyzed their
susceptibility to HIV1 infection once they had returned to a
quiescent state. In spite of achieving equal if not higher degrees of
A3G down-regulation compared to Chiu et al., we found no relief
of HIV1 restriction in resting cells. We can only speculate on the
bases of the discrepancy between the two sets of results. However,
it is worth noting that transfection can be toxic in primary T cells,
leading to cell death, which in turn can induce activation in the
surviving population. Although Chiu and colleagues did not find
any increase in activation markers in transfected cells, it cannot be
excluded that their manipulation triggered the cells to exit from
the G0 to the G1 phase of the cell cycle. This progression, not
monitored in their study, has been shown to suffice for T cells to
become permissive to HIV infection [20]. It could thus have
accounted for their finding of a higher HIV susceptibility of
siRNA-transfected T cells, although this effect would have had to
be specific to the A3G and not control siRNAs.
We cannot formally exclude that the restrictive phenotype
observed in resting post-activation cells has some distinctive
features compared with its counterpart in un-stimulated cells, even
tough the two settings are phenotypically similar. Still, our data
together with results recently published by Kamata et al. [19]
indicate that HIV restriction in resting T cells is not mediated by
A3G. Furthermore, our demonstration that A3G associates with
low and high molecular mass complexes, respectively, in
unstimulated and resting post-activation CD4+ cells, without
differential impact on HIV1 permissiveness, invalidates the
proposed model of an inhibition specifically mediated by LMM-
associated A3G [8]. The mechanisms of HIV restriction in
quiescent T cells as well as the potentially distinct functions of the
two forms of A3G thus remain to be fully elucidated.
Methods
Cells
Human peripheral blood was obtained after written informed
consent by healthy donors from the Centre de Transfusion, Centre
Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Work
with human samples was approved by written consent by the
Ethical Committee of the Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland, and conducted according to
the principles expressed in the Declaration of Helsinki.
Mononuclear cells were isolated from human peripheral blood by
Ficoll-PaqueTM Plus (Amersham Biosciences) density centrifugation
and subjected to negative magnetic selection with CD4+ T Cell
Isolation Kit II (MACS, Miltenyi), following manufacturer instruc-
tions. CD4+ cells were cultured in RPMI-1640 medium (Gibco)
supplemented with 10% Fetal Calf Serum, 2 mM glutamine and
antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). Cells
HIV Block in rT Cells: Not A3G
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Figure 1. Experimental approach. A, CD4+ cells were purified from human peripheral blood (resting), exposed to high-dose IL2 and PHA for two
days (activated) and then maintained for 11–14 days in low-dose IL2 (resting post-act.). B, the three cell populations were analyzed for expression of
activation markers expression (CD25, CD69) (left) and GFP production 3 days after infection with a GFP-containing HIV1 derivative.
doi:10.1371/journal.pone.0006571.g001
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Figure 2. A3G knock-down does not relieve HIV restriction. Activated CD4+ were transduced with HIV vectors expressing Vif, Vif C133S,
shRNA against A3G (shA3G) or mismatched shRNA (sh ctrl), or left untransduced (untr), and let to rest. A. Resting post-activation cells were analyzed
by Western blot for A3G expression. Left panel, two representative experiments out of four performed are shown. Right panel, average and SD of A3G
expression level normalized to PCNA expression level in the Vif or shRNA to A3G transduced cells (KD) and control cells (ctrl) are shown (n = 4). B.
Resting post-activation cells expressing shA3G or Vif (A3G KD), shCtrl or Vif C133S (ctrl), or not previously transduced (untr. ctrl) and activated cells
were infected with GFP- or CFP-expressing HIV reporter virus and analyzed by flow cytometry. Upper and middle panels, two representative
experiments out of four performed are shown. Lower panel, average and SD of the percentage of infected cells in all the experiments are shown
(n = 4). C. Resting, activated and resting post-activation (Rest. post-act.) cells were subjected to ultracentifugation and supernatant (SN) and pellet (P)
from each population were analyzed by Western blot with A3G specific antibody. Upper panel, one representative experiment out of three
performed is shown. Lower panel, average and SD of the ratio between expression level of A3G in the supernatant and the pellet (SN/P ratio) are
shown (n= 3).
doi:10.1371/journal.pone.0006571.g002
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were activated for two days with 100 U/ml IL2 and 5 mg/ml PHA
(both from Sigma-Aldrich) and then cultured for 11–14 days in
decreasing doses of IL-2 (from 100 U/ml to 10 U/ml).
Constructs, viral production and infection
HIV-derived vectors were produced by CaPO4-mediated transient
co-transfection of the lentiviral vector, gag-pol (pCMV. D8.74) and
VSV-G (pMD2.VSV-G) encoding constructs and titered on HEK
293T cells, as previously described (http://tronolab.epfl.ch/; with
minor modifications). For shRNA expression the following puromy-
cin resistance-encoding vectors were used: pLKO.1.shA3G
(TRCN0000052188 clone ID:NM_021822.1-398s1c1; Sigma-Al-
drich) and pRDI292.shA3Gmismatched [21]. For Vif expression
the pRRLsin.cPPT.PGK.GFP-2A-Vif-myc and pRRLsin.cPPT.
PGK.GFP-2A-C133SVif-myc vectors were used [21]. Activated
CD4+ T cells were exposed to vectors at a multiplicity of infection of
3 for an overnight, washed and reseeded in fresh medium. When
using shRNA-expressing vectors, transduced cells were then selected
for three days by using 1.5 mg/ml puromycin (Sigma-Aldrich). When
using Vif expressing vectors transduced cells were sorted by flow
cytometry for GFP expression 3 days after transduction to perform
Western blot or gated on the GFP+ population when performing the
analysis of the single round infection assay.
As fluorescent protein-expressing HIV reporter virus the
pRRLsin.cPPT.PGK.GFP.Wpre [22] or the pRRLsin.cPPT.PGK.
CFP.Wpre (kindly provided by Prof. L. Naldini, San Raffaele Telethon
Institute for Gene therapy, Milan, Italy) vectors were used. Single round
infection assay was performed by exposing the cells to either vector at an
MOI of 3 for an overnight, washing and reseeding them in fresh
medium. Cells were analyzed 3 days after infection by flow cytometry.
Flow Cytometry
The following human-specific conjugated antibodies were used:
fluorescein isothiocyanate (FITC)-CD4 (Dako), allophycocyanin (APC)-
CD25 and phycoerythrin (PE)-CD69 (both from BD Biosciences). To
set gates either isotype controls or untransduced cells were used. At least
10000 events per samplewere analyzedonCyan flowcytometer (Dako).
Western blot
Total proteins were extracted in a radioimmune precipitation
assay buffer (phosphate-buffered-saline (PBS) with 1% NP-40,
0.5% sodium deoxycholate and 0.1% SDS) supplemented with
protease inhibitor cocktail (Calbiochem). Equal amounts of
proteins were resolved on a 10% Bis-Tris NuPage (Invitrogen)
gel followed by Western blot. A3G was detected by the following
polyclonal antibody, obtained through the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH:
Anti-APOBEC3G from Dr. Warner C. Greene [14], followed by a
secondary donkey anti-rabbit antibody conjugated to horseradish
peroxidase. Proliferating cell nuclear antigen (PCNA) was used as
a protein loading control and was detected using a mouse
monoclonal antibody (clone PC10, Calbiochem) followed by a
secondary sheep anti-mouse antibody conjugated to horseradish
peroxidase. A3G band volumes were quantified by ImageQuant
software and normalized to PCNA band volumes.
High Speed Ultracentrifugation
High speed ultracentrifugation was performed as previously
described [16] with minor modifications. Briefly, cells were lysed
with ice-cold lysis buffer (125 mM NaCl, 50 mM, Hepes, pH 7.4,
0.2% NP40, 1 mM dithiothreitol, 0.1 mM PMSF, protease
inhibitor cocktail; Calbiochem) for 30 min and centrifuged at
35,000 rpm (M150SE; Sorvall) for 1.5 h. SN and P were
separated, and P was resuspended in a volume equal to that of
SN. Equal volumes of P and SN were loaded on gel and analyzed
by Western blot (see above).
Acknowledgments
We thank Priscilla Turelli, Yannick Bulliard and Stephanie Jost for advice
and reagents, and Sujana Nylakonda for technical assistance.
Author Contributions
Conceived and designed the experiments: FRSdS DT. Performed the
experiments: FRSdS. Analyzed the data: FRSdS DT. Wrote the paper:
FRSdS DT.
References
1. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, et al. (1990) HIV-1 entry
into quiescent primary lymphocytes: molecular analysis reveals a labile, latent
viral structure. Cell 61: 213–222.
2. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA (1990) HIV-1
replication is controlled at the level of T cell activation and proviral integration.
Embo J 9: 1551–1560.
3. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, et al. (2001)
HIV-1 actively replicates in naive CD4(+) T cells residing within human
lymphoid tissues. Immunity 15: 671–682.
4. Li Q, Duan L, Estes JD, Ma ZM, Rourke T, et al. (2005) Peak SIV replication in
resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature
434: 1148–1152.
5. Nishimura Y, Brown CR, Mattapallil JJ, Igarashi T, Buckler-White A, et al.
(2005) Resting naive CD4+ T cells are massively infected and eliminated by X4-
tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad
Sci U S A 102: 8000–8005.
6. Goff SP (2004) Retrovirus restriction factors. Mol Cell 16: 849–859.
7. Yamashita M, Emerman M (2006) Retroviral infection of non-dividing cells: old
and new perspectives. Virology 344: 88–93.
8. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, et al. (2005) Cellular
APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435:
108–114.
9. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene
that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature
418: 646–650.
10. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad
antiretroviral defence by human APOBEC3G through lethal editing of nascent
reverse transcripts. Nature 424: 99–103.
11. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The
cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1
DNA. Nature 424: 94–98.
12. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004)
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr
Biol 14: 1392–1396.
13. Sheehy AM,Gaddis NC,MalimMH (2003) The antiretroviral enzymeAPOBEC3G
is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404–1407.
14. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks
the antiviral activity of APOBEC3G by impairing both its translation and
intracellular stability. Mol Cell 12: 591–601.
15. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-
Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS
box and upstream cysteines. Genes Dev 18: 2867–2872.
16. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, et al. (2006)
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic
cells to HIV-1 infection. J Exp Med 203: 2887–2893.
17. Korin YD, Zack JA (1999) Nonproductive human immunodeficiency virus type
1 infection in nucleoside-treated G0 lymphocytes. J Virol 73: 6526–6532.
18. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C, et al. (2002) Molecular
characterization of preintegration latency in human immunodeficiency virus
type 1 infection. J Virol 76: 8518–8531.
19. Kamata M, Nagaoka Y, Chen IS (2009) Reassessing the role of APOBEC3G in
human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.
PLoS Pathog 5: e1000342.
20. Korin YD, Zack JA (1998) Progression to the G1b phase of the cell cycle is
required for completion of human immunodeficiency virus type 1 reverse
transcription in T cells. J Virol 72: 3161–3168.
21. Jost S, Turelli P, Mangeat B, Protzer U, Trono D (2007) Induction of antiviral
cytidine deaminases does not explain the inhibition of hepatitis B virus
replication by interferons. J Virol 81: 10588–10596.
22. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by
lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol
sequences. Nat Genet 25: 217–222.
HIV Block in rT Cells: Not A3G
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6571
